Nolan, Patrick

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

Hu, James , Srinivas, Sandy, Costello, Brian A. , Milowsky, Matthew I. , Bromberg, Maria , Nolan, Patrick , Dorff, Tanya B. , Reuter, Victor E. , Bajorin, Dean F. , Feldman, Darren Richard , Stadler, Walter M. , Appleman, Leonard J. , Patil, Sujata N , Al-Ahmadie, Hikmat A , Funt, Samuel A. , Bosl, George J. , Quinn, David I , Motzer, Robert J.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4508-4508

10.1200/jco.2018.36.15_suppl.4508